US 12,252,746 B2
Anti-CD46 antibodies and methods of use
Bin Liu, San Francisco, CA (US); Daniel W. Sherbenou, Denver, CO (US); Blake T. Aftab, Thousand Oaks, CA (US); Yang Su, South San Francisco, CA (US); and Christopher R. Behrens, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jul. 27, 2022, as Appl. No. 17/815,514.
Application 17/815,514 is a division of application No. 16/348,135, granted, now 11,434,301, previously published as PCT/US2017/061124, filed on Nov. 10, 2017.
Claims priority of provisional application 62/421,113, filed on Nov. 11, 2016.
Prior Publication US 2023/0383005 A1, Nov. 30, 2023
Int. Cl. C12Q 1/6886 (2018.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC C12Q 1/6886 (2013.01) [A61K 47/68031 (2023.08); A61K 47/6809 (2017.08); A61K 47/6813 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/00 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); C07K 16/3069 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55 (2013.01); C07K 2317/24 (2013.01); C07K 2317/77 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); G01N 2800/52 (2013.01)] 10 Claims
 
1. A method comprising:
a) determining whether nucleic acid in cancer cells of a subject show a modification at chromosome location 1q21;
wherein a modification at chromosome location 1q21 indicates that the cancer cells are responsive to a CD46-targeted therapy; and
b) administering a therapeutically effective amount of the CD46-targeted therapy, wherein the CD46-targeted therapy is a pharmaceutical composition comprising
(i) an anti-CD46 antibody comprising
a heavy chain variable region comprising a variable heavy (VH) CDR1 that comprises an amino acid sequence of SEQ ID NO: 3, a VH CDR2 that comprises an amino acid sequence of SEQ ID NO: 4, and a VH CDR3 that comprises an amino acid sequence of SEQ ID NO: 5; and
a light chain variable region comprising a variable light (VL) CDR 1 that comprises an amino acid sequence of SEQ ID NO: 6, a VL CDR 2 that comprises an amino acid sequence of SEQ ID NO: 7, and a VL CDR 3 that comprises an amino acid sequence of SEQ ID NO: 8; attached to
(ii) at least one payload wherein the at least one payload comprises an auristatin;
wherein the modification at chromosome location 1q21 is a copy number gain of 1q21.